In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year.
The company said that EPS for next year is anticipated to be between $3.50 and $3.60. On an adjusted basis, EPS is expected in the range of $4.25 to $4.35.
Following completion of the merger with Pall, Danaher plans to split into two publicly traded companies.
Proceeds from the notes offering will be used to pay a portion of the $13.8 billion cost of acquiring Pall.
Upon completion of the deal, Danaher will split into two publicly traded firms, with the life sciences and diagnostics business contained in the company that will retain the Danaher name.
NEW YORK (GenomeWeb News) – Pall today announced an exclusive distribution deal covering India between Pall India and Spinchrom Life Sciences, a division of Spinco Biotech.
Pall last week launched a PCR-based test for microorganisms that cause beer spoilage.
Pall said last week that its GeneDisc assays for Listeria have received performance tested methods certification from the AOAC Research Institute.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Pall today said that it has signed an agreement to acquire protein analysis products firm ForteBio for an undisclosed sum.
A marketing executive for the company said that the GeneDisc system is the first qPCR-based platform on the market to simultaneously detect several indicator pathogens as required by the US Pharmacopeia.
Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.
The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.
US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.
In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.